会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明公开
    • NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    • NEUARTIGE INHIBITORVERBINDUNGEN DER PHOSPHODIESTERASE TYP 10A
    • EP2970328A1
    • 2016-01-20
    • EP14709320.7
    • 2014-03-12
    • AbbVie Deutschland GmbH & Co. KGAbbVie Inc.
    • JANTOS, KatjaOCHSE, MichaelGENESTE, HervéFROGGETT, JayneJAKOB, ClarissaDRESCHER, KarlaDINGES, Jürgen
    • C07D495/04A61K31/5025A61P25/00
    • C07D495/04
    • The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof: (I). In formula I the variables X
      1 is CH or N, X
      2 is O or S and where R
      1 , R
      2 , R
      3 , R
      4 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    • 本发明涉及式I化合物,N-氧化物,互变异构体,前药及其药学上可接受的盐:在式I中,变量X1是CH或N,X2是O或S,并且其中R1,R2,R3 R4和Q如权利要求中所定义。 式I化合物,N-氧化物,互变异构体,其前药和药学上可接受的盐是10A型磷酸二酯酶的抑制剂。 因此,本发明还涉及式I化合物,N-氧化物,互变异构体,前药和其药学上可接受的盐在制备药物中的用途,因此其适用于治疗或控制医学病症 选自神经障碍和精神障碍,用于改善与这种障碍相关的症状并降低这种障碍的风险。
    • 8. 发明公开
    • NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    • NEUARTIGE INHIBITORVERBINDUNGEN DER PHOSPHODIESTERASE TYP 10A
    • EP2895489A1
    • 2015-07-22
    • EP13765695.5
    • 2013-09-16
    • AbbVie Deutschland GmbH & Co. KGAbbVie Inc.
    • GENESTE, HervéOCHSE, MichaelDRESCHER, KarlaJAKOB, ClarissaTORRENT, Maricel
    • C07D491/04C07D495/04C07D498/04A61K31/502A61P25/00
    • C07D471/14A61K31/4985C07D491/04C07D491/14C07D495/04C07D495/14C07D498/04C07D498/14C07D513/14
    • The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. where in formula I the variables X, Y, Q
      1 , Q
      2 have the following meanings: X is C-R
      3 or N; Q
      1 is S or O and Q
      2 is C-R
      4 or N and Q
      2 is connected to X via a double bond while Q
      1 is connected to X via a single bond; or Q
      2 is S or O and Q
      1 is C-R
      4 or N and Q
      1 is connected to X via a double bond while Q
      2 is connected to X via a single bond; Y is C-R
      5 or N; where in formula I the variables R
      1 , R
      2 , R
      3 , R
      4 and R
      5 are as defined in the claims The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    • 本发明涉及式I化合物,N-氧化物,互变异构体,前药及其药学上可接受的盐。 在式I中,变量X,Y,Q1,Q2具有以下含义:X为C-R3或N; Q1是S或O,Q2是C-R4或N,Q2通过双键连接到X,而Q1通过单键连接到X; 或Q2是S或O,Q1是C-R4或N,并且Q1通过双键连接到X,而Q2通过单键连接到X; Y为C-R5或N; 在式I中,变量R1,R2,R3,R4和R5如权利要求中所定义。式I化合物,N-氧化物,互变异构体,其前药和药学上可接受的盐是磷酸二酯酶10A型和 用于制造药物,因此其适用于治疗或控制选自神经障碍和精神障碍的医学病症,用于改善与此类障碍相关的症状并降低此类疾病的风险。